Effectiveness of Diosmin, Cumarin and Arbutin in Reducing Edema and Pain After Hip or Knee Arthroplasty

Backgound/Objectives: to assess the efficacy of a product containing Diosmine, Cumarin and Arbutin (Linfadren®) in reducing edema and pain and improving specific symptomatology in patients undergoing rehabilitation treatment after hip or knee arthroplasty. Methods: in this monocentric prospective study, fifty consecutive patients, hospitalized for rehabilitation, were administered Linfadren® twice a day for 20 days. Limb circumference, pain and specific symptomatology were assessed at baseline and at the end of the treatment; the specific symptomatology was evaluated by means of Western Ontario and McMaster Universities Arthritis Index (WOMAC), self-administered. Results: baseline and final limb circumference showed a statistically significant difference with 60.42 ± 6.77 cm vs 53.7 ± 6.37 cm; P < 0.0001. Baseline and final pain showed a statistically significant difference with NRS 4.0 ± 1.01 vs 0.4 ± 0.70 – P < 0.0001. Baseline and final specific symptomatology differed in statistically significant manner being the respective scores 37.1 ± 14.4 vs 18.1 ± 11.4; P < 0.0001. No deep venous thrombosis event occurred. Conclusions: the product containing Diosmine, Cumarine and Arbitin demonstrates being efficacy in reducing edema and pain and in improving specific symptomatology in patients undergoing rehabilitation treatment after hip or knee arthroplasty. This is relevant for clinical rehabilitation as improves patients’ specific conditions thus making them able to better perform intensive physiotherapy protocols, enhancing the recovery; moreover, it could also play a role in preventing deep venous thrombosis.